STOCK TITAN

Ra Medical's Electrophysiology Division Announces First Use of New Product

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Catheter Precision's LockeT Successfully Used in Series of Patients

FORT MILL, SC / ACCESSWIRE / March 6, 2023 / Ra Medical Systems, Inc. (RMED:NYSE/American) announced today that its wholly owned subsidiary, Catheter Precision, Inc., has announced the first series of procedures using the new LockeT device. Catheter Precision announced that shipping would begin on the week of February 13th and the first procedures would begin shortly thereafter. Within the first week, about thirty of the LockeT devices were used in electrophysiology procedures.

LockeT is used in procedures that require internal access via a venous puncture. These procedures are often associated with catheter insertion, such as those done during electrophysiology procedures like atrial fibrillation or ventricular tachycardias. The first thirty devices were used in the closure of percutaneous sites during procedures that included atrial fibrillation ablations, Watchman™ procedures, and a Lariat™ procedure. The Watchman and Lariat procedures are generally classified as structural heart procedures, as these devices are used for occlusion of the heart's left atrial appendage.

"Whenever a new product is used for the first time, it is exciting", said David Jenkins, CEO. "Gathering the initial feedback from physicians and seeing months of development work come to fruition is fulfilling not just for Catheter Precision, but for patients, because it provides physicians with new options that may provide more benefits. Adding LockeT to our product portfolio allows us to positively impact millions of patients and provide physicians with easy to use, cost effective alternatives to existing products and can be used in different procedures, with both small and large catheter insertion sites."

About Ra Medical Systems

Ra Medical, and its wholly owned subsidiary Catheter Precision, is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

CONTACTS:

At the Company

David Jenkins
973-691-2000
mhuck@catheterprecision.com

SOURCE: Ra Medical Systems, Inc.



View source version on accesswire.com:
https://www.accesswire.com/741956/Ra-Medicals-Electrophysiology-Division-Announces-First-Use-of-New-Product

Ra Medical Systems, Inc.

NYSE:RMED

RMED Rankings

RMED Latest News

RMED Stock Data

3.84M
4.60M
36.85%
11%
1.26%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Carlsbad

About RMED

advanced excimer laser-based vascular and dermatological therapies we are a commercial-stage medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. we believe our products enhance patients’ quality of life by restoring blood-flow in arteries and clearing chronic skin conditions. we currently manufacture and market two lines of products: dabra catheter and laser is cleared by the u.s. fda as a tool for the minimally invasive endovascular treatment of vascular blockages resulting from lower extremity vascular disease, which includes peripheral artery disease (pad), which commonly occurs in the legs. pharos excimer laser pharos is designed for use in the treatment of inflammatory skin conditions and is fda cleared as a tool used in the treatment of psoriasis, atopic dermatitis, and leukoderma. our goal is to become the leading medical device company marketing excimer lasers as tools for the treatment of